Key result
Subcutaneous ICDs were associated with a similar rate of device-related complications and inappropriate shocks compared to transvenous ICDs (15.4% vs 19.2%; HR 1.18, 95% CI 0.22-6.19).
Why the study?
Transvenous ICDs carry risk of lead complications, prompting the need to evaluate the safety and efficacy of subcutaneous ICDs as an alternative in an Asian population.
Does the use of subcutaneous ICDs compared to transvenous ICDs reduce device-related complications and inappropriate shocks in adult patients with indications for single-chamber ICDs without pacing indications?
Cohort (n=39)
No
Does the use of subcutaneous ICDs compared to transvenous ICDs reduce device-related complications and inappropriate shocks in adult patients with indications for single-chamber ICDs without pacing indications?
Hazard Ratio: 1.18 (95% CI 0.22–6.19)
Absolute Event Rate: 15.4% vs 19.2%
In an Asian cohort of patients eligible for ICDs without pacing indications, S-ICDs demonstrated comparable safety and efficacy to TV-ICDs.
S-ICDs showed comparable outcomes to TV-ICDs in Asian patients; leaves open need for randomized confirmation before broader adoption.
BACKGROUND: Transvenous implantable cardioverter-defibrillators (TV-ICDs) are associated with complications from intravenous leads. Subcutaneous ICDs (S-ICDs) were developed as a safer, effective alternative. This study evaluated the efficacy and safety of S-ICDs in an Asian population. METHODS: In this single-center retrospective study, we reviewed adult patients with indications for single-chamber ICDs who did not require pacing or have pace-terminable ventricular tachycardia. Propensity score matching in a 1:2 ratio was applied to compare patients with S-ICDs and TV-ICDs. The primary outcome was a composite of device-related complications and inappropriate shocks. Secondary outcomes included all-cause mortality, appropriate shock therapy, and heart failure hospitalization. RESULTS: From 2020 to 2024, 110 patients (13 with S-ICDs and 97 with TV-ICDs) met inclusion criteria. After propensity score matching, 13 S-ICD and 26 TV-ICD patients were analyzed (82.1 % male; mean age, 43.7 ± 14.2 years). The primary outcome occurred in 15.4 % of the S-ICD group and 19.2 % of the TV-ICD group (hazard ratio [HR], 1.18; 95 % confidence interval [CI], 0.22-6.19). Device-related complications were observed in 1 S-ICD and 4 TV-ICD patients (HR, 0.79; 95 % CI, 0.09-7.24), while inappropriate shocks occurred in 1 patient in each group (HR, 2.45; 95 % CI, 0.15-39.72). Appropriate shocks were delivered in 4 S-ICD and 7 TV-ICD patients (HR, 1.56; 95 % CI, 0.45-5.47). CONCLUSION: Among patients eligible for ICDs without pacing indications, S-ICDs demonstrated comparable safety and efficacy to TV-ICDs, with no significant differences in device-related complications or inappropriate shocks.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2025) conducted a cohort in Indications for single-chamber ICDs without pacing requirements (n=39). Subcutaneous implantable cardioverter-defibrillators (S-ICDs) vs. Transvenous implantable cardioverter-defibrillators (TV-ICDs) was evaluated on Composite of device-related complications and inappropriate shocks (HR 1.18, 95% CI 0.22-6.19). Subcutaneous ICDs were associated with a similar rate of device-related complications and inappropriate shocks compared to transvenous ICDs (15.4% vs 19.2%; HR 1.18, 95% CI 0.22-6.19).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: